The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for patients with an ...
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their ...
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...
Pfizer and Arvinas' Veppanu Gets FDA OK Alongside Guardant Health CDx for ESR1-Mutated Breast Cancer
The agency's decision was based on data from the VERITAC-2 trial, which showed Veppanu improved progression-free survival by nearly three months over fulvestrant.
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
This week in Other Barks & Bites: the U.S. Trade Representative issues its annual Special 301 Report listing the European ...
Pfizer (PFE) stock and Arvinas (ARVN) stock are in focus as the FDA approves the companies' breast cancer drug, Veppanu. Read ...
Arvinas and Pfizer received approval from the Food and Drug Administration for Veppanu, the companies' jointly developed advanced breast cancer treatment. Arvinas said Friday the FDA approved the drug ...
VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable ...
Merck (NYSE:MRK) is expanding in allergy and rare disease markets, including chlorpheniramine maleate and pancreatic ...
Most patients with systemic sclerosis require treatment with multiple modes of action, according to a presenter at Congress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results